Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098295 | 0.81 | GAA (0.54) | KIF11LMNAALDH1A1MAPK1HTT | |
| SCHEMBL14227525 | 0.79 | ENPP2 (0.48) | KIF11ENPP2ALDH1A1SMN1; SMN2PTGS2 | |
| SCHEMBL2376239 | 0.79 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL12860655 | 0.79 | ALDH1A1 (0.48) | KIF11LMNAALDH1A1ESPL1POLB | |
| SCHEMBL17689398 | 0.78 | ALDH1A1 (0.64) | KIF11ENPP2ALDH1A1SMN1; SMN2PTGS2 | |
| SCHEMBL7937243 | 0.78 | ALDH1A1 (0.52) | KIF11LMNAALDH1A1MAPK1HTT | |
| SCHEMBL517720 | 0.78 | ALDH1A1 (0.52) | KIF11LMNAALDH1A1MAPK1HTT | |
| SCHEMBL10145040 | 0.77 | ALDH1A1 (0.69) | KIF11LMNAALDH1A1MAPK1HTT | |
| SCHEMBL8505532 | 0.77 | LMNA (0.44) | KIF11LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL1098294 | 0.76 | LMNA (0.50) | KIF11LMNAALDH1A1MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308605-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-2336107-B1 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2015-09-23 | — | — | EP | disclosed |
| EP-1803709-B1 | PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308605-B2 | Proton pump inhibitors | HRH2, HRH4, HRH1 | KIF11 3160/4885ENPP2 2783/4885LMNA 3457/4885 |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | KIF11 3911/4885ENPP2 2350/4885LMNA 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.